Firmonertinib
Firmonertinib is an oral, brain-penetrant, mutant-selective inhibitor of EGFR. It targets a broad spectrum of EGFR mutations, including exon 20 insertions and the T790M resistance mutation. Firmonertinib is being developed as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions.
| Trivial name | Alflutinib, Furmonertinib, AST2818 |
| Catalog Number | E5881 |
| Molecular Formula | C24H30O3 |
| CAS# | 1869057-83-9 |
| Inchi | InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1 |
| Inchi Key | METQSPRSQINEEU-HXCATZOESA-N |
| SMILES | CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C |
| Size | 100mg |
| Supplier Page | http://www.selleckchem.com/products/firmonertinib.html |
| Additional Information | https://file.selleck.cn/downloads/struct/E5881-Firmonertinib-chemical-structure.png |